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SUMMARY. Since the molecular cloning of the hepatitis C
virus (HCV) genome for the ﬁrst time in 1989, there has
been tremendous progress in our understanding of the
multiple facets of the replication cycle of this virus. Key to
this progress has been the development of systems to
propagate the virus in cell culture, which turned out to be
a notoriously difﬁcult task. A major breakthrough has
been the construction of subgenomic replicons that
self-amplify in cultured human hepatoma cells. These
RNAs recapitulate the intracellular steps of the HCV rep-
lication cycle and have been instrumental to decipher
details of the RNA ampliﬁcation steps including the iden-
tiﬁcation of key host cell factors. However, reproduction of
the complete viral replication cycle only became possible
with the advent of a particular molecular HCV clone
designated JFH-1 that replicates to very high levels
and supports the production of infectious virus particles.
The availability of this new culture system raises the
question, whether the use of replicons is still justiﬁed. In
this review, we will discuss the pros and cons of both
systems.
Keywords: HCV cell culture system, HCVcc, hepatitis C virus,
replicon system.
INTRODUCTION
The hepatitis C virus (HCV) is an enveloped positive-strand
RNA virus of the genus Hepacivirus within the family Flavi-
viridae [1]. Primary infections with HCV are often asymp-
tomatic or associated with only mild symptoms, but they
mostly become persistent causing chronic liver disease [2,3],
which may lead to liver cirrhosis and hepatocellular carci-
noma. At present, more than 170 million people suffer from
chronic hepatitis C [4] making HCV infection a global health
problem. Current treatment consists of a combination of
polyethylene glycol-conjugated interferon-alpha and ribavi-
rin [4], but patients have to endure serious side effects (re-
viewed in Ref. [5]). In addition, success rates are limited and
the outcome of therapy very much depends on the genotype
of the infecting virus [6].
After the ﬁrst molecular cloning of the HCV genome in
1989 [7], the development of speciﬁc antiviral therapies
appeared to be within reach. However, progress in drug
development was slowed down very much by the lack of
systems to propagate HCV in cell culture (HCVcc). Hopes to
establish such systems were high with the construction of
infectious molecular HCV clones [8,9], but their replication
competence demonstrated in experimentally inoculated
animals could not be conﬁrmed in cultured cells (reviewed in
Ref. [10], see Table 1).
HCV REPLICONS OF THE FIRST GENERATION
A major step forward towards establishment of a robust and
reliable cell culture system for HCV was therefore the devel-
opment of subgenomic and selectable HCV replicons [11]. By
deﬁnition, a replicon is a nucleic acid (which can be DNA or
RNA) that is capable of autonomous replication. In this sense,
the HCV genome itself can be regarded as a replicon. How-
ever, for clarity, in this review, we refer to replicons as RNA
molecules capable only of intracellular self-replication, i.e.
unable to support the production of infectious HCV particles.
Key to the establishment of the HCV replicon system was a
molecularly cloned full length genome, designated Con1,
in which the region encoding for the proteins core to
nonstructural protein 2 (NS2) or p7 was replaced by two
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(neo) gene that allows to select for resistance against the
drug G418 and second, the internal ribosome entry site
(IRES) from a picornavirus (Fig. 1A a,b,c). The resulting
construct was bicistronic with the ﬁrst cistron encoding the
neo gene and the second, the HCV replicase genes (NS3–
NS5B). Upon transfection of the human hepatoma cell line
Huh-7 with in vitro transcripts derived from the cloned
replicon cDNA and subsequent G418 treatment, it became
possible to select for a few G418-resistant colonies that
supported HCV RNA replication to unexpectedly high levels
(1000–5000 positive-strand RNA molecules per cell). Rep-
lication of these RNAs was resistant against actinomycin D
which blocks DNA-dependent, but not RNA-dependent RNA
synthesis thus providing formal proof that the HCV replicons
indeed replicated autonomously in these cells.
Subsequent to the establishment of Con1 replicons, the
same approach was used to generate replicons of other HCV
isolates and nowadays replicons derived from more than
eight isolates and covering genotypes 1a, 1b and 2a are
available (Table 1).
IMPROVEMENTS OF THE REPLICON SYSTEM
Further studies identiﬁed two major prerequisites for efﬁcient
replication of these HCV replicons: ﬁrst, the selection for
replication-enhancing (cell culture adaptive) mutations;
second, the selection for particular Huh-7 cells that are
highly permissive for HCV RNA replication [12]. Adaptive
mutations were found to cluster in four distinct regions of the
HCV polyprotein: in the N-terminus of the NS3 helicase, at
two positions in NS4B and in the centre of NS5A. Recloning
of these mutations into the parental replicon resulted in a
strong increase in RNA replication efﬁciency with the degree
of enhancement depending on the particular mutation or
combination of mutations [13–15]. Interestingly, adaptive
Table 1 In vivo and in vitro replicative capacity of some molecular HCV clones (adapted from Ref. [81])
HCV isolate
In vivo study Cell culture study
Infectivity* References
RNA
replication
(replicon)
Production of
infectious virus References
H77 1a + [8] + (requires adaptive
mutations)
n.r. [21]
H77C 1a + [9] + (requires adaptive
mutations, H77S)
±(H77S) [65,82]
HCV-1 1a + [83] ) n.r. [84]
BK 1b/1a
3¢end

+ [85] + (requires adaptive
mutations)
n.r. [85]
HC-J4 1b ORF/1a
3¢NTRs

+ [86] + (requires adaptive
mutations)
n.r. [87]
HCV-N 1b ± [88] + (insertion in NS5A
confers adaptation)
) [22,77,89]
HCV-CG1b 1b +
 [90] + (DNA-expression
system)
+ (DNA-
expression
system)
[91,92]
Con1 1b + [24] + (more efﬁcient with
adaptive mutations)
±(transient
assay wt Con1)
) (adapted Con1)
[11,93],
T. Pietschmann and
R. Bartenschlager,
unpublished results
HC-J6(CH) 2a + [94] ) n.r. [66]
JFH-1 2a +
 [28] ++ + (more efﬁcient with
adaptive mutations)
[26,28,29,33]
JFH-1 based
chimeras
See Fig.
1B a
+
(J6-JFH-1)

[27] ++ ++ (J6-JFH-1),
+ (Con1-JFH-1),
±(H77-JFH-1),
±(452-JFH-1)
[30,31,33]
n.r., not reported. *Infectivity was tested by inoculation of in vitro transcripts into the liver of chimpanzees or mice with
human liver xenografts with cell culture grown HCV.
Chimeric HCV genomes.
Only cell culture grown virus was tested for
infectivity.
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2 I. Woerz et al.mutations at very similar or even identical positions were
found in all replicons based on HCV isolates of genotype 1
established so far, indicating that the mechanisms underlying
cell culture adaptation is conserved within this genotype
(Table 1). The second determinant for efﬁcient RNA replica-
tion turned out to be the selection for highly permissive cells
[14,16,17]. In a given Huh-7 pool, only a few cells appear to
support HCV RNA replication to a high level and G418
selection results in an enrichment of these permissive cells.
Replicon RNAs can be removed from such cell clones by drug
treatment resulting in so-called cured Huh-7 cells that
support HCV RNA replication to a higher level as compared
with the parental cells. Two prominent examples of such cell
clones are Huh7.5 and Huh7-Lunet [16,18].
The availability of highly permissive cell clones and
adaptive mutations greatly broadened the scope of HCVcc
systems. For instance, reporter replicons containing the
luciferase gene and applicable for transient (short-term)
assays became available (Fig. 1A d) [13,14]. In addition, cell
lines containing stably replicating reporter replicons were
generated that are well applicable for high-throughput
screening purposes (Fig. 1A e) (reviewed in Ref. [19]).
Monocistronic replicons were constructed as well, containing
only the HCV IRES and thereby closely mimicking the
translational properties of authentic viral genomes (Fig. 1A f)
[20]. Moreover, it became possible to generate stable cell
clones carrying self-replicating genomic replicons expressing
all viral proteins [16,21–23]. However, attempts to demon-
strate HCV particles released into the culture supernatant of
these cells failed. This is due to the fact that cell culture
adaptive mutations interfere with the production of infectious
virus particles (T. Pietschmann and R. Bartenschlager,
unpublished results). In line with this observation, a Con1
genome containing such adaptive mutations was unable to
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Fig. 1 (A) Structures of hepatitis C virus (HCV) replicons. (a) Schematic presentation of the HCV genome. 5¢ and 3¢NTR are
indicated by white bars. (b) and (c) Structures of bicistronic selectable subgenomic replicons. They are composed of the HCV
5¢NTR directing translation of the neo gene, the IRES of the encephalomyocarditis virus (E-I), the HCV replicase genes NS3–
NS5B (a) or NS2–NS5B (b) and the 3¢NTR. (d) Structure of a subgenomic Con1 reporter replicon that is used for transient
replication assays. Shown is a luciferase (Luc) reporter replicon that contains three cell culture adaptive mutations (indicated
with asterisks) to enhance RNA replication [14]. (e) Structure of a selectable reporter replicon. This construct encodes a
luciferase–ubiquitin–neomycin phosphotransferase fusion protein in the ﬁrst cistron. The RNA supports stable expression
of luciferase; ubiquitin (ubi) is used to trigger proteolytic removal of the neomycin phosphotransferase from the fusion protein.
(f) Structure of a monocistronic reporter replicon. A gene encoding luciferase is fused in frame to the viral replicase genes
NS3–5B via ubiquitin. The entire polyprotein is translated by the HCV IRES. (B) Structure of JFH-1 derived genomes. (a)
Chimeric genomes are composed of the region encoding core to transmembrane segment 1 of NS2 (C3 position) of HCV
isolates Con1, H77 or J6 fused to the remainder of the JFH-1 isolate. In case of the 452 chimera, the region encoding core to
the C-terminus of NS2 (C6 position) was fused to the JFH-1 replicase genes. Junction sites are indicated by an arrow. The
highly assembly competent J6/JFH-1 chimera is also called Jc1 [31]. (b) Schematic representation of a bicistronic full length
JFH-1 reporter genome. The HCV 5¢NTR directs translation of the ﬁreﬂy luciferase gene (Luc) whereas translation of the
HCV polyprotein is under the control of the EMCV IRES (E-I). (c) Schematic diagram of a monocistronic Renilla luciferase
(RLuc) reporter genome [38]. (d) Structure of a monocistronic Jc1 reporter virus applicable for live cell imaging. The gene
encoding the green ﬂuorescent protein (GFP; striped box) is inserted in-frame into domain 3 of NS5A [40].
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Hepatitis C virus replicon system 3establish productive infection in vivo whereas chimpanzees
inoculated with the wild type Con1 genome were readily
infected [24].
THE INFECTIOUS VIRUS SYSTEM (HCVcc)
Inspite of great progress with HCV replicons, the lack of virus
production was an obvious limitation of this system. Because
of the assembly block imposed by adaptive mutations on one
hand, and the very low (most often nondetectable) replica-
tion of nonadapted replicons on the other hand, a full-cycle
culture system only became possible with the identiﬁcation
of an HCV isolate that was capable of high-level replication
without requiring cell culture-adaptive mutations. This holy
grail was discovered by Kato et al. [25], who cloned a
genotype 2a consensus genome designated JFH-1 from a
Japanese patient with fulminant hepatitis. For reasons still
not understood, replicons derived from this isolate replicate
to exceptionally high levels without requiring adaptive
mutations [26]. Most importantly, transfection of JFH-1 full-
length genomes into Huh-7 cells supports the production of
virus particles that are infectious in cell culture and inocu-
lated animals (chimpanzee and transgenic mice with human
liver xenografts), conﬁrming that cell culture-derived HCV
particles (designated HCVcc) represent authentic virions
[27–29].
IMPROVEMENTS OF THE HCVcc SYSTEM
In the light of the rather low infectivity titres attained with
JFH-1 [about 10
4 tissue culture infectious dose 50 (TCID50)
per mL], much effort was made to improve the system. One
major progress was the generation of virus chimeras con-
sisting essentially of the JFH-1 replicase (NS3–NS5B) fused to
the core to NS2 region of other HCV isolates (Fig 1B a).
Lindenbach et al. [30] described a chimera consisting of the
structural region of a genotype 2a isolate [J6 (CF)] fused to
the JFH-1 replicase. Pietschmann and colleagues identiﬁed a
more efﬁcient fusion site (designated C3) and enlarged the
panel of virus chimeras to the isolates Con1 (gt 1b), H77 (gt
1a), 452 (gt 3a) and J6 (gt 2a) (Fig.1B a). Virus titres of the
most efﬁcient intragenotypic chimera that was designated
Jc1 are in the range of 10
6 TCID50/mL [31], i.e. about 100-
fold higher compared with JFH-1.
Alternative to virus chimeras, cell culture adaptation of
JFH-1 by continuous passage of persistently infected cells
allowed the construction of highly efﬁcient JFH-1 variants
that also support virus production to much higher levels as
compared with the parental JFH-1 [29,32–35]. Finally, the
identiﬁcation of proper Huh-7 cell clones was again a key for
a robust HCVcc system as it was for the replicons. Two
notable examples are Huh7.5 and Huh7-Lunet/CD81 high.
The latter are derived from Huh7-Lunet cells by stable over-
expression of CD81, which is required for efﬁcient infection
[36]. Recently, a novel human hepatoma cell line, LH86,
was shown to be susceptible to HCV infection and supporting
HCV RNA replication [37].
In analogy to HCV replicons, JFH-1 derived virus genomes
with insertions of reporter genes have been described (Fig.1B
b,c) [28,38,39]. Moreover, genomes with a stably inserted
gene encoding for the green ﬂuorescent protein were gen-
erated allowing the live visualization of HCV infected cells
[40] (Fig. 1B d).
OTHER CELL-BASED HCV SYSTEMS
Amongst the other available model systems to study HCVcc,
the pseudoparticle system (HCVpp) is perhaps the most
important one [41,42] (Fig. 2). HCVpps are retroviral
nucleocapsids surrounded by a lipid envelope that contains
authentic HCV glycoprotein complexes. As the early steps of
the viral replication cycle are driven by the envelope proteins
largely independent from the other structural proteins,
HCVpp is an ideal system to study receptor binding and entry
and has been used intensively to characterize neutralizing
antibodies.
Very recently, Steinmann et al. [43] described the pro-
duction of HCV-like particles (referred to as HCVTCP) that are
composed of authentic virus particles that contain a subge-
nomic RNA. Upon infection of Huh-7 cells, these RNAs
p p V C H
pli e Rn o c
m e t s y s
c c V C H
Fig. 2 Schematic representation of the HCV replication
cycle and steps that can be addressed with the various cell
culture systems. Upon binding to a permissive host cell [73],
HCV particles enter the cell most likely by receptor-mediated
endocytosis [62]. The RNA genome is liberated into the
cytoplasm and translation occurs at the ER membrane [19].
Upon processing of the polyprotein, the membranous rep-
lication complex is formed (membranous web; MW). [10]
This complex is the site of viral RNA ampliﬁcation. Positive
strand RNA progeny is encapsidated [12] and virus particles
appear to be released from the cell by the constitutive
secretory pathway [81]. Steps of the replication cycle that
can be studied with HCVpp, replicons or the HCVcc system
are indicated by shaded areas or the outer box respectively.
Scheme from Darius Moradpour with slight modiﬁcations.
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4 I. Woerz et al.replicate to high levels, yet do not produce infectious prog-
eny because of the deletion of the structural genes. This
system is also well suited to study the early and late steps of
infection, but does not require a biosafety level 3 laboratory
as is the case for full-length HCV sequences.
Another system to study the HCV replication cycle in a
more authentic setting is the infection of primary human
hepatocytes (PHH). Successful infection could be demon-
strated with serum- and cell culture-derived HCV particles
[44,45]. However, preparation of PHH is a time-consuming
andlaborious process,the quality of PHH is difﬁcult tocontrol
and genome replication of JFH-1 viruses is about 1 order of
magnitude lower in PHH compared with Huh-7.5 cells [45].
Prior to the establishment of HCV replicons, surrogate
models have been used, in particular, the pestivirus bovine
viral diarrhoea virus (BVDV) that shares many features with
HCV such as the genome organization and the overall rep-
lication cycle. As BVDV can easily be cultured in vitro, it has
been a promising model system (reviewed in Ref. [46]). An
additional surrogate model is based on GB virus B (GBV-B),
one of the closest genetic relatives to HCV within the Flavi-
viridae family. GBV-B replicons have been constructed that
are similar to those developed for HCV, but propagation of
infectious GBV-B is also only possible in primary cell cultures
(reviewed in Ref. [47]).
THE PROS AND CONS OF THE HCV REPLICON
AND THE HCVcc SYSTEM
With the plethora of cell-based HCV replication systems
developed in the past few years, most notably the HCVcc
system, the question arises asto which role replicons will play
in the future both in basic and applied research. At a ﬁrst
glance, the HCVcc system is superior because it covers the
complete viral replication cycle (Fig. 2). However, the early
steps (virus binding, entry, uncoating) can already be
addressed with the HCVpp system (Fig. 2). In fact, most, if not
all observations made with the HCVpp system have been
conﬁrmed by using cell culture grown HCV particles. For
instance, CD81 and scavenger receptor B class I have been
validated as important entry molecules (reviewed in Ref.
[48]). Moreover, the essential role of claudin-1 in HCV entry
was recently identiﬁed by using HCVpp and veriﬁed by HCVcc
[49]. Finally, HCV entry via a low pH-dependent step origi-
nally described with HCVpp has now been conﬁrmed with
HCVcc [39,42,50]. Nevertheless, because of the higher
authenticity, most future studies will analyse HCV infection
primarily by using cell culture grown HCV. Moreover, when
using a highly assembly competent HCV variant, the pro-
duction of high titre HCVcc stocks is easier compared with
HCVpp stocks, which cannot be passaged but rather must be
generated by repeated DNA transfection.
When considering RNA replication (Fig. 2), results
obtained with the HCVcc system or the replicon system will
likely be the same. For instance, the important role of lipids
for RNA replication observed with subgenomic replicons has
been conﬁrmed in the HCVcc system [51,52]. Likewise, the
dependence of HCV replication on cyclophilins was found
both in the replicon system and with HCVcc [53–55].
Depending on the particular question, one system may be
superior over the other. For instance, when performing
knock-down experiments of a particular host cell factor, the
impact of the knock-down often is easier to detect in an
infection-based system rather than in the replicon system.
This is due to the fact that upon infection, only few virus
genomes enter the cell, especially when using a low multi-
plicity of infection. In this setting, a limiting host cell factor
will impose a much higher barrier to RNA ampliﬁcation
compared with cells with a stable replicon where the RNA
copy number is already high and where stable replication
complexes have already been formed. Still, replicons will
remain indispensable to analyse the mechanistic roles of host
factors, NS proteins and cis-acting elements in RNA repli-
cation compared with other stages of the viral life cycle.
Probably, the strongest impact the HCVcc system has
deals with the late steps of the replication cycle, i.e. assembly
and release. These aspects could not be addressed properly
by any of the surrogate systems. Although the formation of
virus-like particles had been described in insect cells upon
infection with recombinant baculoviruses or in mammalian
cells upon transfection with alphavirus vectors directing the
expression of the HCV structural genes, none of these sys-
tems adequately reﬂects authentic HCV assembly [56,57].
This is best illustrated by the fact that in none of these sys-
tems, virus (-like) particles were secreted. In contrast,
infectious particles are readily assembled in the HCVcc sys-
tem and some variants support high titres. Taking advan-
tage of that system, it soon became clear that HCV particles
assemble in close proximity of the surface of lipid droplets
where the majority of core protein accumulates [58–60].
Infectious virus particles appear to acquire their envelope by
budding into the lumen of the endoplasmic reticulum in
close apposition to lipid droplets and are released from the
cell in close association with the very-low-density lipoprotein
pathway [61]. Apart from these insights into the peculia-
rities of HCV assembly, the possibility to produce infectious
virus particles in the laboratory under well-deﬁned condi-
tions opens new avenues to visualize infectious HCV. In this
respect, there is no alternative to the HCVcc system. How-
ever, increasing evidence points to important roles of HCV
NS proteins, particularly NS5A, in viral assembly and
subgenomic replicons will remain valuable tools to dissect
the different functions of these proteins [33,62–64].
The major limitation of the HCVcc system is its restriction
to a single isolate (JFH-1) that supports efﬁcient virus pro-
duction. Although, production of infectious particles has also
been described for a highly adapted H77 (genotype 1a) iso-
late, virus titres attained with this genome and infectivity of
released particles appear to be very low [65]. In that respect,
HCV replicons cover a broader range of isolates and
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Hepatitis C virus replicon system 5genotypes (Table 1), particularly of genotype 1, which is
most common worldwide. The availability of such a
spectrum of systems is probably most important for the
development of antiviral drugs. In fact, subgenomic HCV
replicons contain the prime drug targets: the NS3 protease
and the NS5B RdRp. Moreover, replicons are more amenable
for genetic manipulation such as the construction of chi-
meras in which the protease or polymerase gene is replaced
by the corresponding gene from another HCV isolate or even
from genomes isolated from an infected patient. In contrast,
work in our laboratory has shown that replacing, e.g. the
NS3 protease gene of JFH-1 by the one of another func-
tional HCV clone in all cases very much reduced or
completely abolished virus assembly (A. Kaul, A.L. Gamer
and R. Bartenschlager, unpublished results). Likewise, as the
NS5B gene of JFH-1 appears to be a major determinant for
efﬁcient RNA replication, replacements by NS5B genes from
other HCV isolates are very difﬁcult [20,66]. In contrast,
such replacements have been described for subgenomic
replicons derived, e.g. from Con1 and utilized to established
phenotypic resistance assays [67,68].
Because of the high genetic ﬂexibility of replicons, they
can be designed with much more ease as compared with full
length virus genomes. For instance, selectable replicons with
a stably expressed reporter gene (Fig. 1A e) have been used
for high throughput drug screening purposes (reviewed
in Ref. [19]). Because of the easy read-out and the robust
signal, such assays can be automated and adjusted to
robotics, which is important not only for drug screening but
also for screening of large-scale small interfering RNA li-
braries in search for host cell factors required for HCV rep-
lication [69,70]. Moreover, replicons do not impose a
biohazard allowing screening purposes under the lowest
biosafety levels, which is not possible when working with the
HCVcc system. In case of the latter, a high throughput
screen will also require the prior large-scale production of
infectious virus stocks, which may be challenging even
when using highly assembly competent variants such as Jc1.
Hepatitis C virus replicons have also been very instru-
mental to select for antiviral drug resistance. In most cases,
selectable replicons have been used in which the selection
marker (e.g. G418 for neo replicons) is exploited to preserve
the replicon in the face of selective pressure imposed by an
antiviral compound, resulting in the selection of cell clones
with conserved mutations in the viral RNA. In contrast,
when using the HCVcc system, this is not really possible
because a strong antiviral compound with a high genetic
barrier will rapidly eliminate the virus from the culture
(A. Kaul and R. Bartenschlager, unpublished results). Fur-
thermore, if mutations at independent positions confer
resistance, it will be hard to identify relevant mutations in
the viral quasispecies. Although the construction of bicis-
tronic selectable JFH-1 genomes that support the production
of infectious virus particles is possible [71], replication of
such genomes is extremely impaired and virus titres are very
low. Therefore, such genomes will be rapidly lost when
passaging cells in the presence of an antiviral compound (A.
Kaul and R. Bartenschlager, unpublished results).
Possible limitations originally described for HCV replicons
are the restriction to Huh-7 cells and the dependence on host
cell growth. With respect to cell lines, stable replication (by
using selectable replicons) has now been achieved for a
number of other cell lines such as human hepatoma cells
(HuH6 or LH86 [37,72]), human nonliver cells (HeLa or 293
[73–75]), nonhuman liver cells (Hepa1–6 [75]) and non-
human nonliver cells (mouse embryonic ﬁbroblasts [76]).
Moreover, the inhibition of HCV replication that was
observed in conﬂuent nondividing Huh-7 cells has not been
found in HuH6 [72] and HeLa [77] cells. The underlying
reasons are not quite clear, but may be because of limiting
nucleoside triphosphate pools in resting Huh-7 cells [78]. It
should be pointed out that the same observations have been
made when using JFH-1 derived replicons and the full length
genome. In fact, virus production also ceases in conﬂuent
Huh-7 cells and efﬁcient replication and spread is largely
restricted to particular Huh-7 cell clones. Thus, these limi-
tations are no peculiarities of certain replicons, but rather
reﬂect some properties of HCV replication in certain host cells.
PERSPECTIVES
There is no doubt that the possibility to produce recombinant
infectious HCV particles in the laboratory opens new avenues
to study the viral replication cycle. The early and late steps
can now be targeted by inhibitors of virus binding and fusion
[79] or assembly and release [80]. The construction of virus
chimeras composed of the JFH-1 replicase and the structural
region of other isolates has broadened the scope of the HCVcc
system, which is particularly helpful when studying neu-
tralizing antibodies [28]. However, a major limitation is the
restriction to a single genotype 2a isolate, which from a drug
development point of view is least interesting because of the
rather high sustained viral response rates to current therapy
of patients infected with genotype 2 viruses. Construction of
replicase chimeras so far were of limited success and further
studies will be required to overcome that hurdle and to
identify novel molecular HCV clones replicating to high level
in cell culture and supporting the production of infectious
particles. At least until then, but most probably beyond this
time point, the replicon system will be a valuable and
important tool for basic and applied research.
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